On Friday, Shares of Micron Technology, Inc. (NASDAQ:MU), gained 1.85% to $15.96, after the chairman of China’s Tsinghua Unigroup came to the U.S. this week to discuss a potential takeover of the semiconductor manufacturer, sources told Reuters.
Micron had formerly rejected Uniongroup’s informal $23 billion takeover bid in July, due to its belief in the unlikelihood that the deal would receive U.S. regulatory approval due to national security concerns.
Micron technology makes computer chips used in U.S. military weapons systems.
Earlier this month, U.S. Senator Charles Schumer (D) asked the congressional Committee on Foreign Investment in the U.S (CFIUS) to reject the bid, joining Senator John McCain (R) in raising concerns about the deal.
Uniongroup chairman Zhao Weiguo will visit policy experts in Washington D.C. as part of his trip to the country before returning to China next week, according to Reuters.
Micron Technology, Inc., together with its auxiliaries, provides semiconductor solutions worldwide. The company manufactures and markets dynamic random access memory (DRAM), NAND flash, and NOR flash memory products; and packaging solutions and semiconductor systems.
Shares of Merck & Co. Inc. (NYSE:MRK), inclined 0.76% to $55.37, during its last trading session.
Merck & Co. known as MSD outside the United States and Canada, in conjunction with the U.S. Consumer Product Safety Commission (CPSC) recently asked that all customers, counting patients, inspect all bottles of TEMODAR® (temozolomide) capsules and all bottles of Temozolomide capsules (generic) for potential cracks in the child-resistant bottle caps. The medicine is manufactured by Merck and distributed in the United States by Merck as TEMODAR. The Temozolomide capsules (generic) are manufactured and packaged by Merck but sold and distributed by Sandoz, the authorized generic partner, under the Sandoz label. In addition to these supplies, Merck also provides TEMODAR in the United States in sachets (or pouches); TEMODAR in sachets are not affected.
Merck believes that about 1,100 bottles out of an estimated 276,000 distributed bottles of TEMODAR and Temozolomide capsules (generic) could potentially have cracked caps. Those bottles could be at wholesalers, pharmacies, healthcare providers or with patients. The bottle label will say it is offered by Merck & Co. or by Sandoz (for the generic).
Merck & Co., Inc. provides health care solutions worldwide. The company offer therapeutic and preventive agents to treat cardiovascular, type 2 diabetes, asthma, nasal allergy symptoms, allergic rhinitis, chronic hepatitis C virus, HIV-1 infection, fungal infections, intra-abdominal infections, hypertension, arthritis and pain, inflammatory, osteoporosis, male pattern hair loss, and fertility diseases.
Finally, Tesla Motors, Inc. (NASDAQ:TSLA), ended its last trade with 2.26% gain, and closed at $248.48.
Tesla Motors has secured a North American supply of lithium hydroxide through a long-term contract with mining company Bacanora Minerals Ltd. and Rare Earth Minerals PLC, giving the electric carmaker a key base material used to produce lithium-ion batteries used its electric vehicles, according to WSJ.
Tesla is building a $5 billion battery factory in Nevada that aims to reduce battery costs by 30% or more, partly by bringing in in-house materials suppliers. The agreement with the two companies gives Tesla access to below-market-rate lithium in exchange for minimum purchase amounts over a five-year period, according to a statement. WSJ Reports
Tesla Motors, Inc. designs, develops, manufactures, and sells electric vehicles, electric vehicle powertrain components, and stationary energy storage systems in the United States, China, Norway, and internationally.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties, which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified with such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should/might occur.
